AIP
ABUS icon

Ameritas Investment Partners’s Arbutus Biopharma ABUS Stock Holding History

Ameritas Investment Partners’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70.1K Buy
14,597
+1,949
+15% +$8.56K ﹤0.01% 2042
2026
Q1 		$56.9K Hold
12,648
– – ﹤0.01% 2023
2025
Q4 		$60.8K Hold
12,648
– – ﹤0.01% 1992
2025
Q3 		$57.4K Sell
12,648
-2,808
-18% -$10.3K ﹤0.01% 2033
2025
Q2 		$47.8K Buy
15,456
+2,832
+22% +$9.4K ﹤0.01% 2211
2025
Q1 		$44.1K Hold
12,624
– – ﹤0.01% 2175
2024
Q4 		$41.3K Hold
12,624
– – ﹤0.01% 2299
2024
Q3 		$48.6K Hold
12,624
– – ﹤0.01% 2208
2024
Q2 		$39K Buy
12,624
+3,500
+38% +$10.5K ﹤0.01% 2275
2024
Q1 		$23.5K Hold
9,124
– – ﹤0.01% 2493
2023
Q4 		$22.8K Hold
9,124
– – ﹤0.01% 2527
2023
Q3 		$18.5K Hold
9,124
– – ﹤0.01% 2570
2023
Q2 		$21K Hold
9,124
– – ﹤0.01% 2543
2023
Q1 		$27.6K Buy
9,124
+3,000
+49% +$8.46K ﹤0.01% 2326
2022
Q4 		$16.9K Hold
6,124
– – ﹤0.01% 2635
2022
Q3 		$11K Hold
6,124
– – ﹤0.01% 2764
2022
Q2 		$16K Hold
6,124
– – ﹤0.01% 2643
2022
Q1 		$18K Hold
6,124
– – ﹤0.01% 2597
2021
Q4 		$24K Hold
6,124
– – ﹤0.01% 2549
2021
Q3 		$26K Hold
6,124
– – ﹤0.01% 2550
2021
Q2 		$19K Buy
+6,124
New +$19K ﹤0.01% 2751
2019
Q2 		– Sell
-2,944
Closed -$11K – 3045
2019
Q1 		$11K Hold
2,944
– – ﹤0.01% 2654
2018
Q4 		$11K Hold
2,944
– – ﹤0.01% 2620
2018
Q3 		$28K Hold
2,944
– – ﹤0.01% 2324
2018
Q2 		$21K Buy
+2,944
New +$17.5K ﹤0.01% 2476

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ameritas Investment Partners's ABUS Position: Q2 2026 in Review

Ameritas Investment Partners increased its Arbutus Biopharma (ABUS) stake by 15% in Q2 2026, buying an estimated $8.56K and bringing the position to 14,597 shares worth $70.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2042.

Ameritas Investment Partners first reported a position in ABUS in Q2 2018 and has held it in 25 quarters since. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Ameritas Investment Partners held 14,597 shares of Arbutus Biopharma worth $70.1K as of Q2 2026.
  • Ameritas Investment Partners bought 1,949 Arbutus Biopharma shares in Q2 2026, an estimated $8.56K.
  • Arbutus Biopharma made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #2042 holding.
  • Ameritas Investment Partners first reported a position in Arbutus Biopharma in Q2 2018 and has held it in 25 quarters since.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.